UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 969

Sortiert nach

Single-cell analysis of the CD8 + T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69 - subset suggesting potent cytotoxic effectors exist within the tumor bed

Haematologica (Roma), 2024-04, Vol.109 (4), p.1220

2024

Volltextzugriff (PDF)

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

British journal of haematology, 2013-01, Vol.160 (2), p.171-176

2013

Volltextzugriff (PDF)

Treg and Oligoclonal Expansion of Terminal Effector CD8 + T Cell as Key Players in Multiple Myeloma

Frontiers in immunology, 2021-02, Vol.12, p.620596-620596

2021

Volltextzugriff (PDF)

Biology and therapy of multiple myeloma

Medical journal of Australia, 2019-05, Vol.210 (8), p.375-380

2019

Volltextzugriff (PDF)

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Haematologica (Roma), 2012-01, Vol.97 (1), p.64-72

2012

Volltextzugriff (PDF)

The impact of mandatory fortification of flour with folic acid on the blood folate levels of an Australian population

Medical journal of Australia, 2011-01, Vol.194 (2), p.65-67

2011

Volltextzugriff (PDF)

A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission

Oncoimmunology, 2018-04, Vol.7 (4), p.e1419114-e1419114

2018

Volltextzugriff (PDF)

Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse

Clinical lymphoma, myeloma and leukemia, 2024-08, Vol.24 (8), p.543-552.e1

2024

Volltextzugriff (PDF)

Presence of Hoechst low side populations in multiple myeloma

Leukemia & lymphoma, 2008-01, Vol.49 (9), p.1813-1816

2008

Volltextzugriff (PDF)

Multiple myeloma

BMJ (Online), 2012-01, Vol.344 (7840), p.d7953

International edition, 2012

Volltextzugriff (PDF)

Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma

Leukemia & lymphoma, 2009-11, Vol.50 (11), p.1860-1864

2009

Volltextzugriff (PDF)

CMRF-56+ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses

Oncoimmunology, 2016-06, Vol.5 (6), p.e1168555-e1168555

2016

Volltextzugriff (PDF)

Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy

Blood, 2010-04, Vol.115 (17), p.3580-3588

2010

Volltextzugriff (PDF)

Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial

Leukemia & lymphoma, 2012-09, Vol.53 (9), p.1728-1734

2012

Volltextzugriff (PDF)

Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28− compartment

Blood, 2001-11, Vol.98 (9), p.2817-2827

2001

Volltextzugriff (PDF)

Regulatory T Cells and Multiple Myeloma

Clinical lymphoma & myeloma, 2008-10, Vol.8 (5), p.283-286

2008

Volltextzugriff (PDF)

Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?

American journal of hematology, 2006-02, Vol.81 (2), p.110-114

2006

Volltextzugriff (PDF)

Early Serum Free Light Chain (SFLC) Kinetics Is Highly Predictive of Renal Response in Carfilzomib/ Dexamethasone (Cfz/Dex) in Myeloma (MM) Patients with Renal Impairment (RI) — Interim Analysis of the Australian ALLG MM16 Trial

Blood, 2018-11, Vol.132 (Supplement 1), p.3283-3283

2018

Volltextzugriff (PDF)

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

Blood, 2019-11, Vol.134 (Supplement_1), p.2911-2911

2019

Volltextzugriff (PDF)

Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival

Blood, 2001-01, Vol.97 (2), p.490-495

2001

Volltextzugriff (PDF)

Protective Cytotoxic Clonal T-Cells in Myeloma Have the Characteristics of Telomere-Independent Senescence Rather Than an Exhausted or Anergic Phenotype: Implications for Immunotherapy

Blood, 2014-12, Vol.124 (21), p.3367-3367

2014

Volltextzugriff (PDF)

Clonal Cytotoxic T Cells in Myeloma

Leukemia & lymphoma, 2003-01, Vol.44 (10), p.1667-1674

2003

Volltextzugriff (PDF)

Phospho-Flow Cytometry Quantitation of STAT Signalling Checkpoints in Malignant and Non-Malignant Cells Identifies Patients Suitable for pSTAT3 and 5 Targeted Inhibitors

Blood, 2015-12, Vol.126 (23), p.5356-5356

2015

Volltextzugriff (PDF)

A Blood Dendritic Cell Vaccine for Acute Myeloid Leukemia

Blood, 2016-12, Vol.128 (22), p.5221-5221

2016

Volltextzugriff (PDF)

1 – 25 von 969

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(901)
Mit Volltextzugriff
(850)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(645)
Life Sciences & Biomedicine
(476)
Humans
(359)
Female
(205)
Male
(203)
Physical Sciences
(133)
Middle Aged
(129)
Aged
(115)
Adult
(105)
Biological And Medical Sciences
(105)
Medical Sciences
(82)
Animals
(81)
Oncology
(75)
Astronomy & Astrophysics
(70)
Surgery
(68)
Neurosciences & Neurology
(56)
General & Internal Medicine
(53)
Risk Factors
(50)
Science & Technology - Other Topics
(50)
Hematology
(47)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Single-cell analysis of the CD8 + T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69 - subset suggesting potent cytotoxic effectors exist within the tumor bed

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Treg and Oligoclonal Expansion of Terminal Effector CD8 + T Cell as Key Players in Multiple Myeloma

Biology and therapy of multiple myeloma

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

The impact of mandatory fortification of flour with folic acid on the blood folate levels of an Australian population

A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission

Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse

Presence of Hoechst low side populations in multiple myeloma

Multiple myeloma

Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma

CMRF-56+ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses

Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy

Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial

Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28− compartment

Regulatory T Cells and Multiple Myeloma

Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?

Early Serum Free Light Chain (SFLC) Kinetics Is Highly Predictive of Renal Response in Carfilzomib/ Dexamethasone (Cfz/Dex) in Myeloma (MM) Patients with Renal Impairment (RI) — Interim Analysis of the Australian ALLG MM16 Trial

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival

Protective Cytotoxic Clonal T-Cells in Myeloma Have the Characteristics of Telomere-Independent Senescence Rather Than an Exhausted or Anergic Phenotype: Implications for Immunotherapy

Clonal Cytotoxic T Cells in Myeloma

Phospho-Flow Cytometry Quantitation of STAT Signalling Checkpoints in Malignant and Non-Malignant Cells Identifies Patients Suitable for pSTAT3 and 5 Targeted Inhibitors

A Blood Dendritic Cell Vaccine for Acute Myeloid Leukemia

Suchergebnisse filtern